Aug. 29 Company Quick Takes: EC approves Tecentriq for breast cancer, Giapreza for hypotension; plus Innovent reports Tyvyt sales

EC approves Tecentriq for breast cancer
The European Commission approved Tecentriq atezolizumab from Roche (SIX:ROG; OTCQX:RHHBY) in combination with Abraxane nab-paclitaxel for PD-L1-positive unresectable locally advanced or metastatic triple-negative breast cancer (TNBC). The combination is the first immunotherapy regimen in Europe for TNBC. Tecentriq was approved for TNBC in the U.S. in March (see “TNBC Gets Its First Targeted Agent With Tecentriq Approval”).

La Jolla hypotension drug approved in Europe
The EC approved Giapreza angiotensin II from La Jolla Pharmaceutical Co. (NASDAQ:LJPC) to treat refractory hypotension in adults with septic or other distributive shock. FDA approved the renin-angiotensin system peptide agonist in December 2017 (see “FDA Approves La Jolla’s Distributive Shock Therapy")...